 |
인쇄하기
취소
|
Dongwha teams up with Teijin over DW1350
Dongwha Pharm says on April 1 that it entered into a technology transfer agreement with Teijin Pharma under which Teijin will have exclusive rights to develop and commercialize a novel class of molecules for the treatment of osteoporosis in Japan.
The agreement includes Dongwha's novel drug DW1350 and its derivatives.
Under the terms of agreement, Dongwha will receive an upfront fee, dev...
The agreement includes Dongwha's novel drug DW1350 and its derivatives.
Under the terms of agreement, Dongwha will receive an upfront fee, dev...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.